Patents by Inventor Philip A. Gerken

Philip A. Gerken has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • KRAS G12C inhibitors
    Patent number: 12291539
    Abstract: The present disclosure provides compounds and methods useful in the treatment and suppression of cancer, for example, useful for treating or suppressing cancers characterized by KRAS G12C. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: July 24, 2024
    Date of Patent: May 6, 2025
    Assignee: Frontier Medicines Corporation
    Inventors: Snahel Patel, Philip A. Gerken, Monika Jane Williams
  • METHODS FOR TREATMENT OF CANCER
    Publication number: 20250129103
    Abstract: The present disclosure provides compounds and methods useful in the treatment and suppression of cancer, for example, useful for treating or suppressing cancers characterized by KRAS G12C. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: February 7, 2023
    Publication date: April 24, 2025
    Inventors: Snahel Patel, Philip A. Gerken, Monika Jane Williams
  • KRAS G12C INHIBITORS
    Publication number: 20250019387
    Abstract: The present disclosure provides compounds and methods useful in the treatment and suppression of cancer, for example, useful for treating or suppressing cancers characterized by KRAS G12C. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Application
    Filed: July 24, 2024
    Publication date: January 16, 2025
    Inventors: Snahel PATEL, Hiroko TANAKA, Daniel A. ERLANSON, Philip A. GERKEN, John C. WIDEN, Monika Jane WILLIAMS, Irina DOTSENKO
  • Ester and carbonate pyrimidine compounds as JAK kinase inhibitors
    Patent number: 11845747
    Abstract: The invention provides compounds of formula (I): or pharmaceutically-acceptable salts thereof, that are inhibitors of Janus kinases and release an active metabolite in vivo. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat inflammatory skin diseases and other diseases.
    Type: Grant
    Filed: September 27, 2021
    Date of Patent: December 19, 2023
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Philip A. Gerken, Jianhua Chao, Daniel D. Long
  • Pyrimidine JAK inhibitors for the treatment of skin diseases
    Patent number: 11439641
    Abstract: The invention provides compounds of formula (I): or pharmaceutically-acceptable salts thereof, that are inhibitors of Janus kinases. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat inflammatory and autoimmune skin diseases.
    Type: Grant
    Filed: April 23, 2020
    Date of Patent: September 13, 2022
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Philip A. Gerken, Jianhua Chao
  • ESTER AND CARBONATE PYRIMIDINE COMPOUNDS AS JAK KINASE INHIBITORS
    Publication number: 20220009926
    Abstract: The invention provides compounds of formula (I): or pharmaceutically-acceptable salts thereof, that are inhibitors of Janus kinases and release an active metabolite in vivo. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat inflammatory skin diseases and other diseases.
    Type: Application
    Filed: September 27, 2021
    Publication date: January 13, 2022
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Philip A. Gerken, Jianhua Chao, Daniel D. Long
  • Ester and carbonate pyrimidine compounds as JAK kinase inhibitors
    Patent number: 11155549
    Abstract: The invention provides compounds of formula (I): or pharmaceutically-acceptable salts thereof, that are inhibitors of Janus kinases and release an active metabolite in vivo. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat inflammatory skin diseases and other diseases.
    Type: Grant
    Filed: April 23, 2020
    Date of Patent: October 26, 2021
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Philip A. Gerken, Jianhua Chao, Daniel D. Long
  • PYRIMIDINE JAK INHIBITORS FOR THE TREATMENT OF SKIN DISEASES
    Publication number: 20200338073
    Abstract: The invention provides compounds of formula (I): or pharmaceutically-acceptable salts thereof, that are inhibitors of Janus kinases. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat inflammatory and autoimmune skin diseases.
    Type: Application
    Filed: April 23, 2020
    Publication date: October 29, 2020
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Philip A. Gerken, Jianhua Chao
  • ESTER AND CARBONATE PYRIMIDINE COMPOUNDS AS JAK KINASE INHIBITORS
    Publication number: 20200339580
    Abstract: The invention provides compounds of formula (I): or pharmaceutically-acceptable salts thereof, that are inhibitors of Janus kinases and release an active metabolite in vivo. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat inflammatory skin diseases and other diseases.
    Type: Application
    Filed: April 23, 2020
    Publication date: October 29, 2020
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Philip A. Gerken, Jianhua Chao, Daniel D. Long